Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) released its earnings results on Wednesday. The company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.09, FiscalAI reports. The firm had revenue of $65.00 million for the quarter, compared to analysts’ expectations of $32.78 million. Kymera Therapeutics had a negative return on equity of 21.82% and a negative net margin of 285.33%.The business’s revenue for the quarter was up 465.2% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.95) earnings per share.
Here are the key takeaways from Kymera Therapeutics’ conference call:
- KT-621’s atopic dermatitis Phase IIb trial completed enrollment six months early, with top-line data now expected by year-end 2026 and Phase III initiation targeted for mid-2027. Management believes the oral, once-daily profile could substantially expand systemic treatment in type 2 inflammatory diseases.
- The asthma Phase IIb trial is enrolling and remains on track for top-line results by late 2027, while an open-label extension will provide up to 52 additional weeks of safety and efficacy data. The company also expects KT-579 healthy-volunteer data in Q4 2026 before advancing into lupus proof-of-concept studies.
- Partnered programs continue to advance, including Sanofi’s KT-485 Phase I start, which generated a $20 million milestone, and Gilead’s $45 million option exercise fee. Gilead’s KT-200 is expected to enter clinical development next year.
- Kymera ended June with approximately $1.5 billion in cash and investments and reiterated a cash runway into 2029. Management expects this funding to support current Phase II programs, KT-579 through lupus proof of concept, and the beginnings of KT-621 Phase III development.
- The company recognized all currently deferred collaboration revenue in the second quarter, totaling $65 million, and does not expect additional revenue in 2026 absent new milestones. R&D cash spending rose 22% sequentially to $109.1 million as clinical investment increases.
Kymera Therapeutics Price Performance
NASDAQ KYMR traded up $1.11 on Friday, reaching $107.52. The company had a trading volume of 463,562 shares, compared to its average volume of 736,421. The firm has a market cap of $8.84 billion, a price-to-earnings ratio of -33.19 and a beta of 1.95. Kymera Therapeutics has a fifty-two week low of $36.65 and a fifty-two week high of $130.05. The business has a 50 day moving average of $100.79 and a two-hundred day moving average of $88.66.
Analysts Set New Price Targets
Read Our Latest Stock Report on KYMR
Insider Buying and Selling
In other news, CEO Nello Mainolfi sold 80,000 shares of the stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $115.29, for a total value of $9,223,200.00. Following the completion of the sale, the chief executive officer owned 666,568 shares of the company’s stock, valued at approximately $76,848,624.72. This represents a 10.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Bvf Partners L. P/Il sold 1,578,800 shares of the stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $106.50, for a total value of $168,142,200.00. Following the completion of the sale, the director directly owned 240,123 shares of the company’s stock, valued at approximately $25,573,099.50. The trade was a 86.80% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 3,607,813 shares of company stock valued at $387,818,004 over the last 90 days. 15.98% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD raised its position in shares of Kymera Therapeutics by 20.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock worth $479,258,000 after acquiring an additional 1,061,957 shares in the last quarter. Commodore Capital LP bought a new stake in shares of Kymera Therapeutics during the 2nd quarter valued at about $32,730,000. Alyeska Investment Group L.P. grew its stake in Kymera Therapeutics by 1,130.2% during the third quarter. Alyeska Investment Group L.P. now owns 615,091 shares of the company’s stock worth $34,814,000 after purchasing an additional 565,091 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Kymera Therapeutics by 121.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company’s stock worth $24,535,000 after purchasing an additional 491,737 shares during the period. Finally, Millennium Management LLC increased its holdings in Kymera Therapeutics by 340.4% in the first quarter. Millennium Management LLC now owns 510,480 shares of the company’s stock worth $13,972,000 after purchasing an additional 394,562 shares in the last quarter.
About Kymera Therapeutics
Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.
The company’s pipeline emphasizes immunology and oncology.
Featured Stories
- Five stocks we like better than Kymera Therapeutics
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
